

1 **Inactivation of highly pathogenic avian influenza virus with high temperature short time**  
2 **continuous flow pasteurization and virus detection in bulk milk tanks**

3

4 Short title: Inactivation of HPAIV by continuous flow pasteurization

5

6 Erica Spackman<sup>1\*</sup>, Nathan Anderson<sup>2</sup>, Stephen Walker<sup>2\*</sup>, David L. Suarez<sup>1</sup>, Deana R. Jones<sup>3</sup>, Amber

7 McCoig<sup>4</sup>, Tristan Colonius<sup>4</sup>, Timothy Roddy<sup>5</sup>, Nicholas J. Chaplinski<sup>3</sup>

8

9 1. Exotic and Emerging Avian Viral Disease Research Unit, Southeast Poultry Research Center, US

10 National Poultry Research Center, USDA-Agricultural Research Service, Athens, GA, USA

11 2. Office of Food Safety, Center for Food Safety and Applied Nutrition, US Food and Drug

12 Administration, Bedford Park, IL, USA

13 3. US National Poultry Research Center, USDA-Agricultural Research Service, Athens, GA, USA

14 4. Center for Veterinary Medicine, US Food and Drug Administration, Rockville, MD, USA

15 5. Office of State Cooperative Programs, US Food and Drug Administration, Kansas City, MO, USA

16

17

18 \*Corresponding authors:

19 For inquiries related to avian influenza, bulk tank testing, virological and molecular methods:

20 Erica.Spackman@usda.gov

21 For inquiries related to pasteurization: Stephen.Walker@fda.hhs.gov

22

23

24

25

26 **Abstract**

27 Infections of dairy cattle with clade 2.3.4.4b H5N1 highly pathogenic avian influenza virus (HPAIV)  
28 were reported in March 2024 in the U.S. and viable virus was detected at high levels in raw milk from  
29 infected cows. This study aimed to determine the potential quantities of infectious HPAIV in raw  
30 milk in affected states where herds were confirmed positive by USDA for HPAIV (and therefore were  
31 not representative of the entire population), and to confirm that the commonly used continuous flow  
32 pasteurization using the FDA approved 72°C (161°F) for 15 s conditions for high temperature short  
33 time (HTST) processing, will inactivate the virus. Double-blinded raw milk samples from bulk  
34 storage tanks from farms (n=275) were collected in four affected states. Samples were screened for  
35 influenza A using quantitative real-time RT-PCR (qrRT-PCR) of which 158 (57.5%) were positive  
36 and were subsequently quantified in embryonating chicken eggs. Thirty-nine qrRT-PCR positive  
37 samples (24.8%) were positive for infectious virus with a mean titer of 3.5 log<sub>10</sub> 50% egg infectious  
38 doses (EID<sub>50</sub>) per mL. To closely simulate commercial milk pasteurization processing systems, a  
39 pilot-scale continuous flow pasteurizer was used to evaluate HPAIV inactivation in artificially  
40 contaminated raw milk using the most common legal conditions in the US: 72°C (161°F) for 15s.  
41 Among all replicates at two flow rates (n=5 at 0.5L/min; n=4 at 1L/min), no viable virus was  
42 detected. A mean reduction of  $\geq 5.8 \pm 0.2$  log<sub>10</sub> EID<sub>50</sub>/mL occurred during the heating phase where the  
43 milk is brought to 72.5°C before the holding tube. Estimates from heat-transfer analysis support that  
44 standard U.S. continuous flow HTST pasteurization parameters will inactivate >12 log<sub>10</sub> EID<sub>50</sub>/mL of  
45 HPAIV, which is ~9 log<sub>10</sub> EID<sub>50</sub>/mL greater than the mean quantity of infectious virus detected in raw  
46 milk from bulk storage tank samples. These findings demonstrate that the milk supply is safe.

47

48

49

50 **Key words**

51 Influenza A; highly pathogenic avian influenza; raw milk; cows; pasteurization; high temperature  
52 short time (HTST)

53

54 **Abbreviations**

55 BHI=brain heart infusion; BMRT = Bulk Mean Residence Time; CFR=Code of Federal Regulations;  
56 ECE = embryonating chicken egg; EID50= 50% egg infectious dose; FPRT = Fastest Particle  
57 Residence Time; HPAIV= highly pathogenic avian influenza virus; HTST = high temperature short  
58 time; IFSH = Institute for Food Safety and Health; qrRT-PCR=quantitative real-time reverse  
59 transcription polymerase chain reaction; 50% tissue culture infectious doses=TCID50. USNPRC=US  
60 National Poultry Research Center

61

62 **Introduction**

63 Highly pathogenic avian influenza virus (HPAIV) was reported in dairy cow herds in the U.S. in  
64 March of 2024 and virus was subsequently detected in raw milk (*Burrough et al., 2024*). An April  
65 2024 targeted study of retail fluid milk and dairy products reported that virus could be detected by  
66 quantitative real-time reverse transcription polymerase chain reaction (qrRT- PCR) based methods in  
67 approximately 20% of the products but no infectious virus was detected (*Spackman et al., 2024*).  
68 Therefore, it is critical to understand the prevalence and potential quantities of infectious virus that  
69 could occur along each stage of the milk supply.

70 Bulk tanks are large storage tanks used to cool and store milk from the herd on a dairy farm  
71 until it can be picked up for processing. Larger farms can pump directly to tanker trucks to facilitate  
72 transfer to the processing plant. Tanks and tanker trucks have the capacity to hold milk from 600-700  
73 cows. After transport to processing plants, milk is clarified and filtered, then separated so the milk fat  
74 can be standardized to the required content for the final product. Finally, the standardized product is

75 homogenized at high pressure, which requires heating to 55-80°C. Homogenization occurs in-line  
76 with pasteurization, so the two processes occur together continuously.

77 Cows on larger farms are also closely monitored for feed consumption, milk production, and  
78 rumen activity; sick cows are separated for further attention. Cows with clinical mastitis, cows with  
79 abnormal milk quality, or sick cows undergoing treatment are milked separately so that the milk can  
80 be diverted from entering the human food supply. However, individual HPAIV infected cows that  
81 appear healthy have been observed (*Ashby, 2024*) and could potentially excrete virus into their milk,  
82 and cows that recover from infection and are returned to the general population may still shed viral  
83 RNA for extended periods of time.

84 Pasteurization, which uses heat to kill pathogenic bacteria, has been a public health success to  
85 greatly reduce human infections related to the consumption of dairy products (*FDA, 2019*).  
86 Previously, there have been no studies on inactivation of avian influenza virus in milk, but based on  
87 pasteurization times in egg product it was expected that HPAIV in milk would be inactivated at  
88 common pasteurization times and temperatures (*Chmielewski et al., 2011; Chmielewski et al.,*  
89 *2013; Thomas and Swayne, 2009*). However, recent studies attempting to simulate pasteurization  
90 conditions at the benchtop scale have reported inconsistent results. Guan *et al.*, described a 4.5 log<sub>10</sub>  
91 50% tissue culture infectious dose reduction after 15 s at 72°C but infectious virus could be recovered  
92 beyond 15 s from milk with higher initial titers (*Guan et al., 2024*). Similarly, another study reported  
93 a reduction of 4 log<sub>10</sub> TCID<sub>50</sub>/mL in 5 s at 72°C, and infectious virus could still be detected to 20  
94 seconds (*Kaiser et al., 2024*). In contrast to the other studies, another found complete inactivation at  
95 72°C in 15 s with log reductions up to 7.75 log<sub>10</sub> EID<sub>50</sub>/mL of an H5 virus in raw milk was reported  
96 (*Cui et al., 2024*). As the authors of these reports recognize, because these studies were conducted  
97 using PCR thermocyclers, the studies do not directly replicate commercial pasteurization conditions.  
98 Therefore, the objectives of this study were to determine the potential quantities of infectious HPAIV  
99 in bulk tank milk and to assess the efficacy of continuous flow pasteurization under conditions that

100 closely approximate commercial milk pasteurization processing at high temperature short time  
101 (HTST), 72°C (161°F) for 15 s.

102

### 103 **Materials and Methods**

104 **Collection of bulk tank milk samples.** In collaboration with four states, the U.S. Food and Drug  
105 Administration (FDA) secured raw milk bulk tank samples over a two-week period April 18-27, 2024.  
106 Samples were taken from farms known to be affected as well as farms not known to be affected.  
107 Samples were collected as “universal samples” as a routine procedure anytime milk was offered for sale,  
108 by licensed personnel, as part of state participation in the Pasteurized Milk Ordinance (*FDA, 2019*)  
109 regulatory system. Each sample was blinded and sent by state regulatory personnel to the Institute for  
110 Food Safety and Health (IFSH, Bedford Park, IL) where they were double-blinded and aggregated prior  
111 to shipment to the U.S. National Poultry Research Center (USNPRC) for analysis. These states had herds  
112 with HPAIV H5N1 infections confirmed by USDA. Sampling occurred in regions known to include  
113 affected farms and was neither random nor representative of prevalence.

114 **Quantitative real-time RT-PCR for influenza A.** Upon receipt, double-blinded bulk tank  
115 samples were assigned a unique accession number and processed for RNA extraction as described  
116 using a hybrid procedure with Trizol LS (Thermo Fisher Scientific, Waltham, MA) and the MagMax  
117 magnetic bead kit (*Spackman et al., 2024*). VetMAX Xeno (Thermo Fisher Scientific) was added to  
118 the Trizol LS for each reaction prior to sample addition to serve as an extraction control and an  
119 internal positive control. Each sample was run on quantitative real-time RT-PCR (qrRT-PCR) assay  
120 on a QuantStudio5 (Thermo Fisher Scientific) using a test targeting the influenza A M gene  
121 (*Spackman et al., 2002*). The primers and probe for the internal control were used as directed by the  
122 Xeno kit instructions. Non-infectious qrRT-PCR based quantity estimates were determined by  
123 including a standard curve derived from RNA extracted from a 10-fold dilutions series of quantified  
124 avian influenza virus stocks propagated in embryonating chicken eggs (*Spackman, 2020*).

125           **Virus detection and quantification in embryonating chickens eggs.** All samples that were  
126 positive for virus detection by qrRT-PCR were processed to determine the quantity of infectious virus  
127 in embryonating chicken eggs (ECE). A portion of each sample (1 mL) was aliquoted and treated for  
128 1 h at ambient temperature (approximately 21°C) with antibiotics at a final concentration of:  
129 penicillin G 1000 IU/ml, streptomycin 200 µg/ml, gentamicin 100 µg/ml, kanamycin 65 µg/ml,  
130 amphotericin B 2 µg/ml. To quantify the virus, 10-fold dilutions were made in brain heart infusion  
131 (BHI) broth with antibiotics using standard methods (*Reed and Muench, 1938; Spackman and Killian,*  
132 *2020*) and hemagglutination assay was used to confirm the presence of avian influenza virus (*Killian,*  
133 *2020*).

134           **Inactivation of HPAIV by HTST continuous flow pasteurization.** Raw milk  
135 (approximately 4.5% milk fat) (Supplementary Table 1) was obtained from the University of Georgia  
136 Dairy (Athens, GA) and immediately transported to the USNPRC for processing. Milk was  
137 homogenized in a Gaulin 15m 8BA (Manton-Gaulin Manufacturing CO., Inc, Everett, MA) at 40°C.  
138 After homogenization, a 3mL sample was collected as a negative control and 5L portions of milk  
139 were prepared and artificially contaminated with a recent US clade 2.3.4.4b HPAIV isolate:  
140 A/turkey/Indiana/22-003707-003/2022 H5N1 (TK/IN/22) (provided by Dr. Mia Torchetti, National  
141 Veterinary Services Laboratories, US Department of Agriculture-Animal and Plant Health Inspection  
142 Service, Ames, IA).

143           A pilot-scale continuous flow pasteurizer modified for inline sampling and cooling  
144 (UHT/HTST Veros™ EDH, MicroThermics®, Raleigh, NC) was installed in an ABSL-3Ag research  
145 space and used to closely simulate commercial milk pasteurization processing systems. The  
146 computer-controlled pasteurizer included a progressive cavity pump, preheater, final heater, hold  
147 tube, cooler, and inline sampling and cooling ports after the final heater and after the product cooler  
148 (Figure 1). Temperature was measured for critical parameters using calibrated thermocouples and  
149 recorded in 10 s intervals by the MicroThermics® system.

150 The artificially contaminated raw, homogenized milk (10 mL of virus stock added to 5 L raw  
151 milk at a titer of  $\sim 9.7 \log_{10} \text{EID}_{50}/\text{mL}$ ) was used to supply the pasteurizer at a flow rate of 0.5 or 1.0  
152 L/min. Flow rate was verified prior to each pasteurization run using a stopwatch and graduated  
153 cylinder. Milk was heated to 37.8°C in the preheater to ensure milk entered the final heater at a  
154 consistent temperature. Milk exited the final heater at 72.5°C and entered the hold tube, the section of  
155 the processor where the product is held for a specific time at a minimum temperature to achieve  
156 pasteurization. At a flowrate of 0.5 L/min, the product in the hold tube had a 15 s fastest particle  
157 residence time (FPRT) and 18 s bulk mean residence time (BMRT) and exited the hold tube at  
158 approximately 72°C, which constitutes the commonly used legal pasteurization treatment known as  
159 HTST (at least 72°C for minimum of 15 s). The higher flow rate of 1 L/min produced a sub-legal  
160 thermal treatment with a FPRT of only 7.5 s. Milk was cooled to approximately 21 to 32°C in the  
161 product cooler and excess milk was collected in sealed buckets for treatment with disinfectant.

162 Each sample set was collected on a different day starting with a fresh batch of raw milk from  
163 the dairy. Prior to each pasteurization run, three independent 3-mL samples were collected from the  
164 milk supplying the pasteurizer to establish the starting titer. During pasteurization run, two or three  
165 samples were collected at the outlet of the final heater, just before the product entered the hold tube.  
166 The inline sampling port cooled the milk in an ice-water bath prior to dispensing into a pre-sterilized  
167 septum bottle. Two or three samples were collected after the hold-tube at the outlet of the cooler  
168 (Table 1). All samples were quantified in ECE as described above. At least four replicate trials were  
169 completed at each flow rate.

170 Alkaline phosphatase activity measured soon after pasteurization is routinely used as an  
171 indicator to confirm that proper minimum pasteurization times and temperatures have been achieved  
172 (Rankin et al., 2010) and was used as an additional confirmation for differences in flow rate. An  
173 alkaline phosphatase test (Fast alkaline phosphatase test Charm Sciences, Inc, Lawrence, MA) read  
174 on the NovaLUM II-X (Charm Sciences, Inc.) was used in accordance with the manufacturer's

175 instructions on the supply milk, pre- and post- hold tube samples two replicates at 72°C 0.5 L/min  
176 and 1 L/min.

177 **Temperature Analysis of Final Heater.** The final heater in the Microthermics® system is a coiled  
178 tube in shell heat exchanger consisting of 13.1 m of 6.35 mm x 0.89 mm (¼ in. x 0.035 in.) wall  
179 tubing. To help account for the lethality that occurs in the final heater section, it is useful to consider  
180 the temperature profile of the product as it passes through the heat exchanger. Using a few simple  
181 equations, the temperature profile across the length of the heater can be estimated. First, the heat  
182 transfer of a shell in tube heat exchanger is described by the following equation (*Heldman and Singh,*  
183 *1981*):

184

$$185 \quad Q = U \times A \times \Delta T_{LM}$$

186 ( 1 )

187 Where  $Q$  is the rate of heat transfer,  $U$  is the overall heat transfer coefficient,  $A$  is the heat transfer  
188 surface area, and  $\Delta T_{LM}$  is the log mean temperature difference between the product and the heating  
189 medium:

$$190 \quad \Delta T_{LM} = \frac{\Delta T_2 - \Delta T_1}{\ln \frac{\Delta T_2}{\Delta T_1}}$$

191 ( 2 )

192 The rate of heat transfer in the heat exchanger is also equivalent to the rate of heat absorbed by the  
193 milk:

$$194 \quad Q = \dot{m} \times C_p \times (T_{final} - T_{initial})$$

195 ( 3 )

196 Where  $\dot{m}$  is the mass flow rate of milk,  $C_p$  is the specific heat of milk, and  $(T_{final} - T_{initial})$  is the  
197 temperature gained in the heat exchanger. Combining equation (1) and (3) and solving for  $U$ :

$$198 \quad U = \frac{\dot{m} \times C_p \times (T_{final} - T_{initial})}{A \times \Delta T_{LM}}$$



199 ( 4 )

200 Using the reasonable assumption that the coefficient  $U$  is constant throughout the length of the heat  
201 exchanger,  $U$  can also be expressed in terms of any product temperature along the length of the heat  
202 exchanger:

$$204 \quad U = \frac{\dot{m} \times C_P \times (T_{intermediate} - T_{initial})}{A_{intermediate} \times \Delta T_{LM \ intermediate}}$$

205 Combining equations (4) and (5) results in an expression that can be solved for the fraction of the heat  
206 exchanger area required to reach an intermediate temperature:

$$207 \quad \frac{A_{intermediate}}{A} = \frac{(T_{intermediate} - T_{initial})}{(T_{final} - T_{initial})} \times \frac{\Delta T_{LM}}{\Delta T_{LM \ intermediate}}$$

208 ( 5 )

209 With a fixed cross-sectional area in the heat exchanger, this fraction also represents the fraction of the  
210 total residence time required to achieve an intermediate temperature. Because the temperature of the  
211 heating water is relatively constant across the heat exchanger, an estimate of residence time starting at  
212 any intermediate temperature can be calculated.

213 **Statistics.** Simple linear regression was used to characterize the relationship between the  
214 qrRT-PCR estimated titer and actual infectious virus (Prism10.2, Graphpad Software, San Diego  
215 CA).

216

## 217 **Results**

218 **Detection and quantification of influenza A in bulk tank milk samples.** A total of 275  
219 samples were tested for influenza A by qrRT-PCR and 158 (57.5%) were positive 107 (38.9%) were  
220 negative, and 10 (3.6%) were invalid (negative for influenza A and the internal control failed)  
221 (Supplementary Table 2). Of the 158 qrRT-PCR positive samples, one was discarded due to bacterial  
222 contamination and 39 (24.8%) were positive for infectious virus with titers from 1.3 to 6.3 log<sub>10</sub>

223 EID<sub>50</sub>/mL and a mean of 3.5 log<sub>10</sub> EID<sub>50</sub>/mL. There was no clear correlation between the estimated  
224 titer by qrRT-PCR and quantified viable virus (R-squared = 0.37) and the amount of live virus grown  
225 in ECE.

226 **Inactivation of HPAIV by continuous flow pasteurization.** Processing conditions during  
227 pasteurization are reported in Table 1. Hold tube outlet temperature (the critical temperature  
228 parameter for pasteurization) was 71.64 ± 0.3°C (160.96 ± 0.50 °F) across all replicate trials at a  
229 flowrate of 0.5 L/min and 72.26 ± 0.15°C (162.07 ± 0.28°F) at 1.0 L per min. Input titers ranged from  
230 6.4 to 7.1 log<sub>10</sub> EID<sub>50</sub>/mL (mean 6.7 ± 0.2 log<sub>10</sub> EID<sub>50</sub>/mL) (Table 1, Supplementary table 3). There  
231 were 5 replicates at 72°C, 0.5 L/min; four replicates at 72°C, 1 L/min.; and, 1 replicate each at 78, 83,  
232 86, and 90°C at 0.5 L/min flow rate (Supplementary table 3). Regardless of target temperature and  
233 flow rate, no infectious virus was recovered from either sample location, before and after the hold  
234 tube. There consistently was an ≥ 5.8 log<sub>10</sub> EID<sub>50</sub>/mL reduction in titer of infectious virus at 72°C.  
235 Alkaline phosphatase was inactivated at 0.5 L/min, but failure to inactivate at the 1 L/min flow rate  
236 confirmed that the thermal treatment was reduced (Supplementary table 3).

237

## 238 **Discussion**

239 When HPAIV was discovered in milk from infected cows (*Burrough et al., 2024*), food safety  
240 concerns were raised as ingestion of contaminated milk could serve as a potential route of exposure  
241 for humans. Therefore, several points along the milk food supply chain were evaluated for the  
242 presence of infectious HPAIV using qrRT-PCR based methods and positive samples were then tested  
243 to quantify infectious virus. Retail milk products were shown to contain no infectious virus in a prior  
244 study (*Spackman et al., 2024*), although 20% of the samples were positive for viral RNA. In the  
245 current study, two additional stages of the milk supply, bulk storage tanks and pasteurization, were  
246 assessed.

247 Because viral RNA has been detected in retail milk samples (*Spackman et al., 2024*), its  
248 detection in bulk tanks was not unexpected. Interestingly, the proportion of samples that were positive

249 for infectious virus was only 24.8% of the samples which were positive by qrRT-PCR. Also, the  
250 quantities of infectious virus were generally lower than what was detected by qrRT-PCR with a mean  
251 of 3.5 log<sub>10</sub> EID<sub>50</sub>/mL. The discrepancy may be due to bacterial digestion of the virus and/or  
252 neutralizing antibodies from infected cows in the milk. Additional research on reliable assays for  
253 neutralizing influenza A antibody detection in raw milk are needed. Also, once cows recover from  
254 infection and return to normal milk production and quality, detectable, but non-infectious, viral RNA  
255 could be present in their milk (personal communication Dr. Mía Torchetti), but research is ongoing.

256 It is important to recognize that the first risk mitigation measure is to remove infected cows  
257 from contributing to the milk supply destined for commercial processing by PMO regulations. Based  
258 on field reports infected cows may develop mastitis or other clinical signs that will trigger diversion  
259 of the cow's milk from the food supply. However, it is expected that early in infection, cows may be  
260 sub-clinical but have virus in the milk. Subclinical infections in cows may also play a role. There is  
261 also data to show that some cows may remain subclinical, but shed virus in the milk (*Ashby, 2024*).  
262 Because identification of infected cows based on clinical signs cannot be 100% reliable, it is likely  
263 that virus contamination of milk will occur and other mitigation measures, such as pasteurization, are  
264 needed to assure a safe milk supply. Because the consumption of raw milk or dairy products is a  
265 known source of bacterial infections, the use of pasteurization has been widely adopted to kill  
266 pathogenic bacteria which greatly increases the safety of milk and dairy products. Because avian  
267 influenza has not been previously reported in milk, no safety data was available, but pasteurization  
268 methods have been reported in egg and egg products that support that temperatures similar to milk  
269 pasteurization are effective at inactivating avian influenza viruses (*Chmielewski et al.,*  
270 *2011;Chmielewski et al., 2013;Swayne and Beck, 2004;Thomas et al., 2008;Thomas and Swayne,*  
271 *2009*). However, recent studies appear to indicate that influenza A may have greater than expected  
272 thermal stability in milk and have reported somewhat inconsistent results for virus inactivation in raw  
273 milk at 72°C using PCR thermal cyclers (*Cui et al., 2024;Guan et al., 2024;Kaiser et al., 2024*).  
274 Therefore, studies that more closely simulate commercial pasteurization are needed to ensure that

275 continuous flow pasteurization, which is widely used by the U.S. dairy industry, is effective at  
276 eliminating infectious virus from milk.

277 An initial pasteurization run was conducted with 72, 78, 83, 86, 90°C at a 0.5 L /min flow  
278 rate and because no viable virus was recovered, all subsequent testing was conducted at the lowest  
279 temperature of 72°C. Importantly, no infectious virus was detected after the final heater (i.e., before  
280 the hold tube) where the milk was heated from 40 to 72.5°C (104 to 162.5°F). The inactivation of  
281 virus in the heating section makes it challenging to estimate the log reduction that might occur in the  
282 holding tube, although it would be expected to be much greater than the reduction achieved during the  
283 ramped heating process.

284 To estimate the lethality that would likely occur in the holding tube, consider that at 1.0 L per  
285 minute, the BMRT in the final heater is 12.9 s. Using the conservative estimates for turbulent flow,  
286 the FPRT in the center of tube is 9.9 s. At an intermediate temperature of 63°C (145°F), Equation 6  
287 results in a fraction of 0.27, meaning that in the first 2.7 s the milk is heating from 40°C (104°F) to  
288 63°C (145°F), and takes the remaining 7.2 s to reach 72.5°C (162.5°F). Data from a recently  
289 published study suggests that the decimal reduction time (D value) of HPAI in milk at 63°C (145°F)  
290 is approximately 20 s (*Kaiser et al., 2024*), so it would be reasonable to assume that there is  
291 negligible reduction in infectious virus during the 2.7 s before it reaches 63°C (145°F), and therefore  
292 the entire inactivation of  $\sim 6 \log_{10} \text{EID}_{50}/\text{mL}$  is achieved during the 7.2 s of ramped heating from  
293 63°C (145°F) to 72.5°C (162.5°F).

294 Commercial pasteurization systems in the U.S. have holding times that are calibrated to the  
295 FPRT using a salt-solution conductivity test (*FDA, 2019*), so that the legal minimum holding times  
296 are achieved even for the fastest particle, as required under Title 21 of the Code of Federal  
297 Regulations (CFR) 1240.61 (*FDA, 1992*). With inactivation of  $\geq 5.8 \log_{10} \text{EID}_{50} / \text{mL}$  in 7.2 seconds  
298 while heating to process temperature, it would be reasonable to expect that a 15 s holding time at a  
299 process temperature of 72°C (161°F) could inactivate  $>12 \log_{10} \text{EID}_{50}/\text{mL}$ .

300           There are several limitations of these studies. First, the bulk tank sampling was limited in  
301 scope to milk from regions known to include affected farms and therefore was biased toward positive  
302 samples and was not designed to determine the prevalence of HPAIV in bulk tank milk at large (i.e.,  
303 nationally representative sample). The sampling did provide a snapshot of the quantity of infectious  
304 virus that could be present in raw milk from affected farms. Second, challenge studies utilizing the  
305 continuous flow pasteurizer utilized high titers introduced into milk instead of milk from infected  
306 cows. High inoculum levels are typically used when conducting inactivation studies to document high  
307 levels of inactivation (*National Advisory Committee on Microbiological Criteria for, 2010*).  
308 Naturally contaminated milk in quantities needed to complete replicates with the pasteurizer with  
309 consistent, high levels of HPAIV, was not available. Conducting challenge studies with inoculated  
310 product is common practice and results with naturally contaminated milk are expected to be similar,  
311 but studies with foot and mouth disease have shown that virus in milk from infected cows was more  
312 stable than virus in artificially contaminated milk (*Sellers, 1969*). Because of the documented thermal  
313 lability of influenza A, and the de minimis thermal resistance exhibited by HPAIV in this study, any  
314 differences are expected to be minimal. Lastly, only whole milk fat content of approximately 4.5%  
315 was tested. Fat could protect the virus, so potentially virus could be more stable in higher-fat cream  
316 products (*Tomasula and Konstance, 2004*). Because of the known protective effect of fat for bacterial  
317 pathogens, higher times and longer temperatures are required for higher fat products (*FDA,*  
318 *2019;FDA, 2024*). Additional studies are needed to accurately characterize the inactivation kinetics  
319 (D- and Z-value) of HPAIV in milk and milk products to assess process lethality under various time-  
320 temperature combinations.

321           This study demonstrated that infectious influenza A can be detected in bulk storage tanks  
322 from HPAIV infected dairy herds and that HTST pasteurization is effective in inactivating this virus  
323 in milk. Importantly, the quantities of infectious virus are generally much lower than what is detected  
324 by qrRT-PCR methods and no infectious virus could be detected in approximately 75% of the  
325 samples that were positive by qrRT-PCR. Approximately 5.8-6 log<sub>10</sub> EID<sub>50</sub> HPAIV was inactivated in

326 the final heater before the holding tube (quantities of around 6-7 log<sub>10</sub> viable units of an organism are  
327 typically used when conducting inactivation studies to document high levels of inactivation (*National*  
328 *Advisory Committee on Microbiological Criteria for, 2010*)). Also, the quantities of virus that were  
329 consistently inactivated in the final heater were approximately 3.0log<sub>10</sub> EID<sub>50</sub> higher than the mean  
330 quantity of infectious virus in this limited set of bulk tank samples. The pasteurization time-  
331 temperature combination in 21 CFR 1240.61 (*FDA, 1992*) and Pasteurized Milk Ordinance (*FDA,*  
332 *2019*) of 72°C for 15s is estimated to result in >12 log reduction of HPAIV in whole milk under  
333 conditions that closely approximate HTST commercial milk pasteurization processing, which is  
334 further supported by the fact that retail milk products were shown to contain no infectious virus  
335 (*Spackman et al., 2024*). These findings together demonstrate that the milk supply is safe. Additional  
336 work will evaluate the effect of homogenization on virus viability and the determination of D- and z-  
337 values for HPAIV in fluid dairy products.

338

### 339 **Acknowledgements**

340 The authors gratefully thank: Frankie Beacorn, Tarrah Bigler, Sydney Birge-Hales, Suzanne DeBlois,  
341 Edna Espinoza, Jesse Gallagher, Javier Garcia, Jessica Gladney, David Haley, Anne Hurley-Bacon,  
342 Lindsay Killmaster, Scott Lee, John Miles, David Miles, Stephen Norris, Phil Paxton, Jodie Ulaszek  
343 Melinda Vonkungthong, Robin Woodruff, Jason Wan, and Ricky Zoller for technical assistance with this  
344 work. We are also very grateful to the University of Georgia Dairy for supplying fresh raw milk, and The  
345 Pennsylvania State University, Department of Food Science for providing the homogenizer.

346 Any use of trade, firm, or product names is for descriptive purposes only and does not imply  
347 endorsement by the US Government. This research was supported by US Department of Agriculture  
348 (USDA)-Agricultural Research Service Project No. 6040-32000-081-00D and the US Food and Drug  
349 Administration by IAA 60-6040-4-005. All opinions expressed in this paper are the authors' and do not  
350 necessarily reflect the policies and views of the USDA or FDA. The USDA and FDA are equal  
351 opportunity providers and employers.

352

353 **References**

- 354 1. Ashby, A. (2024), NCDA&CS lifts isolation of HPAI-positive dairy herd after herd tests negative  
355 for the virus. Available at: [https://www.ncagr.gov/news/press-releases/2024/05/06/ncdacs-lifts-isolation-](https://www.ncagr.gov/news/press-releases/2024/05/06/ncdacs-lifts-isolation-hpai-positive-dairy-herd-after-herd-tests-negative-virus)  
356 [hpai-positive-dairy-herd-after-herd-tests-negative-virus](https://www.ncagr.gov/news/press-releases/2024/05/06/ncdacs-lifts-isolation-hpai-positive-dairy-herd-after-herd-tests-negative-virus). Accessed June 4, 2024.
- 357 2. Burrough, E., D. Magstadt, B. Petersen, S. Timmermans, P. Gauger, J. Zhang, C. Sieper, M.  
358 Mainenti, G. Li, A. Thompson, P. Gorden, P. Plummer, and R. Main. (2024). Highly Pathogenic Avian  
359 Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Domestic Dairy Cattle and Cats, United States,  
360 2024. *Emerging Infectious Disease journal*, 30.
- 361 3. Chmielewski, R. A., J. R. Beck, and D. E. Swayne. (2011). Thermal inactivation of avian  
362 influenza virus and Newcastle disease virus in a fat-free egg product. *J Food Prot*, 74:1161-8.
- 363 4. Chmielewski, R. A., J. R. Beck, and D. E. Swayne. (2013). Evaluation of the U.S. Department of  
364 Agriculture's egg pasteurization processes on the inactivation of high-pathogenicity avian influenza virus  
365 and velogenic Newcastle disease virus in processed egg products. *J Food Prot*, 76:640-5.
- 366 5. Cui, P., Y. Zhuang, Y. Zhang, L. Chen, P. Chen, J. Li, L. Feng, Q. Chen, F. Meng, H. Yang, Y.  
367 Jiang, G. Deng, J. Shi, H. Chen, and H. Kong. (2024). Does pasteurization inactivate bird flu virus in  
368 milk? *Emerg Microbes Infect*, 13:2364732.
- 369 6. FDA. (1992), Code of Federal Regulations, Title 21, Section 1240.61. Available at:  
370 <https://ecfr.io/Title-21/Section-1240.61>. Accessed May 14, 2024, 2024.
- 371 7. FDA. (2019), Grade “A” Pasteurized Milk Ordinance. Available at:  
372 <https://www.fda.gov/media/140394/download>. Accessed May 16, 2024, 2024.
- 373 8. FDA. (2024), Milk Guidance Documents & Regulatory Information. Available at:  
374 [https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-dietary-](https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-dietary-supplements/milk-guidance-documents-regulatory-information)  
375 [supplements/milk-guidance-documents-regulatory-information](https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-dietary-supplements/milk-guidance-documents-regulatory-information). Accessed May 16, 2024, 2024.
- 376 9. Guan, L., A. J. Eisfeld, D. Pattinson, C. Gu, A. Biswas, T. Maemura, S. Trifkovic, L. Babujee, R.  
377 Presler, Jr., R. Dahn, P. J. Halfmann, T. Barnhardt, G. Neumann, A. Thompson, A. K. Swinford, K. M.



- 378 Dimitrov, K. Poulsen, and Y. Kawaoka. (2024). Cow's Milk Containing Avian Influenza A(H5N1) Virus -  
379 Heat Inactivation and Infectivity in Mice. *N Engl J Med*.
- 380 10. Heldman, D., and R. Singh. (1981). Food Process Engineering. The Avi Publishing Company,  
381 Inc., Westport, CT.
- 382 11. Kaiser, F., D. H. Morris, A. Wickenhagen, R. Mukesh, S. Gallogly, K. C. Yinda, E. de Wit, J. O.  
383 Lloyd-Smith, and V. J. Munster. (2024). Inactivation of Avian Influenza A(H5N1) Virus in Raw Milk at  
384 63 degrees C and 72 degrees C. *N Engl J Med*.
- 385 12. Killian, M. L. (2020). Hemagglutination Assay for Influenza Virus. *Methods Mol Biol*, 2123:3-10.
- 386 13. National Advisory Committee on Microbiological Criteria for, F. (2010). Parameters for  
387 determining inoculated pack/challenge study protocols. *J Food Prot*, 73:140-202.
- 388 14. Reed, L. J., and H. Muench. (1938). A simple method for estimating fifty percent endpoints.  
389 *American Journal of Hygiene*, 27:493-497.
- 390 15. Sellers, R. F. (1969). Inactivation of foot-and-mouth disease virus in milk. *Br Vet J*, 125:163-8.
- 391 16. Spackman, E. (2020). Avian Influenza Virus Detection and Quantitation by Real-Time RT-PCR.  
392 *Methods Mol Biol*, 2123:137-148.
- 393 17. Spackman, E., D. R. Jones, A. M. McCoig, T. J. Colonius, I. V. Goraichuck, and D. L. Suarez.  
394 (2024). Characterization of highly pathogenic avian influenza virus in retail dairy products in the US. *J*  
395 *Virology*, Accepted 6-4-24.
- 396 18. Spackman, E., and M. L. Killian. (2020). Avian Influenza Virus Isolation, Propagation, and  
397 Titration in Embryonated Chicken Eggs. *Methods Mol Biol*, 2123:149-164.
- 398 19. Spackman, E., D. A. Senne, T. J. Myers, L. L. Bulaga, L. P. Garber, M. L. Perdue, K. Lohman, L.  
399 T. Daum, and D. L. Suarez. (2002). Development of a real-time reverse transcriptase PCR assay for type  
400 A influenza virus and the avian H5 and H7 hemagglutinin subtypes. *Journal of Clinical Microbiology*,  
401 40:3256-60.
- 402 20. Swayne, D. E., and J. R. Beck. (2004). Heat inactivation of avian influenza and Newcastle  
403 disease viruses in egg products. *Avian Pathol*, 33:512-8.



404 21. Thomas, C., D. J. King, and D. E. Swayne. (2008). Thermal inactivation of avian influenza and  
405 Newcastle disease viruses in chicken meat. *J Food Prot*, 71:1214-22.

406 22. Thomas, C., and D. E. Swayne. (2009). Thermal inactivation of H5N2 high-pathogenicity avian  
407 influenza virus in dried egg white with 7.5% moisture. *J Food Prot*, 72:1997-2000.

408 23. Tomasula, P. M., and R. P. Konstance. (2004). The survival of foot-and-mouth disease virus in  
409 raw and pasteurized milk and milk products. *J Dairy Sci*, 87:1115-21.

410

411


**Table 1.** Summary of HTST continuous flow pasteurization parameters and quantities of infectious highly pathogenic avian influenza virus (HPAIV) in raw homogenized milk supplying the pasteurizer determined by a viability assay conducted in embryonating chicken eggs. Five and four replicates were conducted at flow rates of 0.5 L/min and 1 L/min, respectively. Values reported as mean  $\pm$  standard deviation.

<b>Milk Flowrate (L/min)</b>	<b>Raw Milk Temperature °C (°F)</b>	<b>Preheater Temperature °C (°F)</b>	<b>Final Heater Temperature °C (°F)</b>	<b>Hold Tube Outlet Temperature °C (°F)</b>	<b>Titer of HPAIV in supply milk (Log<sub>10</sub> EID<sub>50</sub>/mL)<sup>a</sup></b>
0.5	30.11 $\pm$ 0.17	39.84 $\pm$ 0.18	72.54 $\pm$ 0.16	71.64 $\pm$ 0.27	6.6 $\pm$ 0.15
	(86.20 $\pm$ 0.32)	(103.71 $\pm$ 0.31)	(162.58 $\pm$ 0.30)	(160.96 $\pm$ 0.50)	
1	31.43 $\pm$ 0.26	40.29 $\pm$ 0.33	72.71 $\pm$ 0.15	72.26 $\pm$ 0.16	6.8 $\pm$ 0.17
	(88.57 $\pm$ 0.45)	(104.52 $\pm$ 0.64)	(162.87 $\pm$ 0.27)	(162.07 $\pm$ 0.28)	

a. Mean of all replicates for each flow rate; EID<sub>50</sub> = 50% Egg infectious doses

## Figure legends

**Figure1.** Schematic of the HTST continuous flow pasteurizer with inline sampling ports.



**Supplementary materials for: Spackman *et al.* Inactivation of highly pathogenic avian influenza virus with high temperature short time continuous flow pasteurization and virus detection in bulk milk tanks**

**Supplementary Table 1.** Analysis of milk used with the continuous flow pasteurizer. Raw milk was run on a LactiCheck™ Rapid Read Milk Analyzer (Weber Scientific, Hamilton, NJ), in accordance with the manufacturer's instructions.

Metric	Batch		
	1	2	3
Temperature (°C)	17.5	16.0	18.6
% Fat	4.45	4.15	4.30
% Solids not fat	9.02	9.17	9.16
Density (in 10XX.XX g/cm <sup>3</sup> )	30.16	31.03	30.85
Connectivity	4.31	4.41	4.42
% Water added	0.00	0.00	0.00
% Protein	3.27	3.34	3.33
Freezing point (°C)	-0.58	-0.59	-0.59
% Solids, salt, others	0.73	0.74	0.74
% Total solids	13.47	13.32	13.46
% Lactose	4.94	5.03	5.02
pH	6.5-7.0	6.5-7.0	6.5-7.0

**Supplementary table 3.** Summary of HPAIV inactivation in homogenized raw milk by continuous flow pasteurization

Batch <sup>a</sup>	Temp (°C)	Flow rate (L per min)	Titer of input milk <sup>b</sup> log <sub>10</sub> EID <sub>50</sub> <sup>c</sup>	Replicate	Virus detection <sup>d</sup> log <sub>10</sub> EID <sub>50</sub>		Alkaline phosphatase test <sup>e</sup>		
					Pre-hold tube	Post-hold tube	Supply milk	Pre-hold tube	Post-hold tube
1	72	0.5	6.8	1	<0.8	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
				3	<0.9	<0.9	Not run	Not run	Not run
1	78	0.5	6.9	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
				3	<0.9	<0.9	Not run	Not run	Not run
1	83	0.5	6.6	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
				3	<0.9	<0.9	Not run	Not run	Not run
1	86	0.5	6.8	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
				3	<0.9	<0.9	Not run	Not run	Not run
1	90	0.5	7.1	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
				3	<0.9	<0.9	Not run	Not run	Not run
2	72	0.5	6.5	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
2	72	0.5	6.6	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
3	72	0.5	6.6	1	<0.9	<0.9	Fail	Pass	Pass
				2	<0.9	<0.9	Not run	Fail	Pass
3	72	0.5	6.4	1	<0.9	<0.9	Fail	Pass	Pass
				2	<0.9	<0.9	Not run	Fail	Pass
2	72	1	6.5	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
2	72	1	6.8	1	<0.9	<0.9	Not run	Not run	Not run
				2	<0.9	<0.9	Not run	Not run	Not run
3	72	1	6.9	1	<0.9	<0.9	Fail	Fail	Fail
				2	<0.9	<0.9	Not run	Fail	Fail
3	72	1	6.8	1	<0.9	<0.9	Fail	Fail	Fail
				2	<0.9	<0.9	Not run	Fail	Fail

a. Each batch is a different day run with fresh raw milk collected that morning.

b. Mean of 3 samples of input milk.

c. EID<sub>50</sub> = 50% Egg infectious doses.

d. Virus viability assay conducted in embryonating chicken eggs.

e. Test used to confirm that pasteurization times and temperatures have been achieved. Test kit: Fast alkaline phosphatase test (Charm Sciences, Inc, Lawrence, MA) read on the NovaLUM II-X (Charm Sciences, Inc.) in accordance with the manufacturer's instructions.